On November 12, the 2022 International Eye Health Technology Innovation and Industry Development Summit Forum and the China Eye Valley Optometry Innovation and Entrepreneurship Global Challenge was held in Longwan, Wenzhou.
It is understood that since the launch of this competition in September, 168 entries from all over the country have been collected. After the fierce competition among the finalists, more than 20 entries have come to the fore, covering the fields of ophthalmic materials, ophthalmic drugs, smart medicine, ophthalmic instruments and equipment, ophthalmic big data platforms, digital therapy, etc.
The roadshow was brilliant. Taking the "Mihe artificial cornea" as an example, "China is one of the countries with an extremely short supply of cornea, and many people are blind because they can't wait to see the cornea. The artificial cornea I bring today can make many patients see the light again..." At the roadshow site of the innovation and entrepreneurship challenge, Yu Ya, the person in charge of Mihe Medical, introduced.
"Mihe keratoprosthesis" is an artificial cornea product independently researched and developed in China and has complete independent intellectual property rights. On December 7, 2021, it won the medical device registration certificate issued by the State Food and Drug Administration. This is the first and only artificial cornea with independent intellectual property rights listed in China.
According to the project review experts, "The comprehensive development of the project is an important measurement standard for this selection. The innovation of the project, or the core competitiveness of technology, is the key to the future development of the project. The quality of a project, its application scenario, the integrity of the project operation team's organizational structure, and the quality of professionals are all important reference values for this project evaluation."
Mihm artificial cornea is made of artificial materials without donor cornea, which is helpful to alleviate the shortage of corneal donors in China. It is suitable for patients with binocular corneal blindness who are difficult to succeed in corneal transplantation, including corneal transplantation failure, severe keratoconjunctival scar vascularization, eyelid atresia, and severe autoimmune diseases (such as Stevens Johnson syndrome and cicatricial pemphigoid) caused by chemical injury, thermal burn, explosive injury, etc, Corneal blindness caused by end-stage dry eye provides a new way for the clinical treatment of patients with contraindications to traditional corneal transplantation.
Mihe artificial cornea won the third prize of 2022 China Eye Valley Optometry Innovation and Entrepreneurship Global Challenge
As a global competition for collecting projects in the field of eye health, the China Eye Valley Eye Vision Innovation and Entrepreneurship Global Challenge has further led the development of the eye health industry, expanded global cooperation in the field of eye health, and input a batch of high-quality resources for Eye Valley to build a world-class scientific innovation and talent highland in the eye health industry.
It is understood that since the launch of the fourth Innovation and Entrepreneurship Challenge held by China Eye Valley in 2019, more than 400 high-level innovation and entrepreneurship teams at home and abroad have been attracted to participate, and a number of projects have been successfully introduced and settled in Eye Valley.